Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jul 15 2020

Full Issue

Perspectives: Despite The Rush, Remdesivir Needs A Large Clinical Trial

Recent commentaries about drug-cost issues.

Bloomberg: U.S. Hospitals Need To Study How Well Remdesivir Really Works 

For months, hospitals have suffered the consequences of the country’s pandemic blunders. Intensive-care units have overflowed. Medical staff have struggled to get personal protective equipment, and have worked beyond exhaustion. It seems unfair to ask them to make up for another government misstep. But U.S. hospitals need to band together to run a clinical trial of the Covid-19 treatment remdesivir, even though the Trump administration has already decided the drug is what all hospitals should be using, going so far as to corner the worldwide market for it. (Peter Bach, 7/13)

Pittsburgh Post-Gazette: Ensure Treatment For All: Government Must Make Coronavirus Drug Accessible

We’re all in this together, or so we are often told when it comes to the coronavirus crisis. If it applies to wearing masks in public and keeping socially distant, it has to apply to a lifesaving medical treatment for COVID-19 as well. That means that remdesivir, the promising anti-viral drug with the recently released eye-popping price tag of about $3,000 a course, has to be accessible for everyone. (7/3)

The American Independent: Prescription Drug Costs Are Skyrocketing. The Senate Isn't Doing Anything About It.

Senate Majority Leader Mitch McConnell has refused to hold a vote on multiple bills to lower prescription drug costs even as prices continue to increase. Since July 1, 42 medications have increased in cost by an average of 3.5%, according to GoodRx, including drugs to treat asthma, diabetes, and high blood pressure. (Dan Desai Martin, 7/13)

The Arizona Republic: Prescription Drug Affordabilty Is A Problem. This Is Not The Answer

Seniors’ access to affordable prescription drugs remains hotly debated in Congress and an issue of high interest in Mesa, home to many aging adults and the district I represent at the Arizona state House. Back in 2003, President Bush and the U.S. Congress found an innovative way to add a Prescription Drug Benefit to Medicare. It is known as Medicare Part D. (Michelle Udall, 7/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF